Cite
HARVARD Citation
Risi, E. et al. (2019). An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic advances in medical oncology. p. . [Online].